Matthias Aizenberg

Matthias Aizenberg

Healthcare Innovation Consultant
Matthias Aizenberg is a seasoned expert in the Healthcare industry. He explores digital health, clinical processes, and healthcare management strategies. Matthias has a deep interest in pharmaceutical and healthcare innovation and is a well-trusted resource for biopharma professionals.
Are Biopharma Hedge Funds the Key to Outperforming the Market?
Management & Regulatory Are Biopharma Hedge Funds the Key to Outperforming the Market?

Investors often seek avenues that can offer significant returns while mitigating risks. The biopharma sector, with its blend of innovation and high stakes, has captured the attention of hedge fund managers and investors alike. But can biopharma hedge funds truly be the key to outperforming the

Are AI and Biotech Innovations Transforming Australian Healthcare?
Tech & Innovation Are AI and Biotech Innovations Transforming Australian Healthcare?

The ongoing evolution of digital technologies offers the potential to profoundly transform the Australian healthcare system, and this promise is becoming increasingly evident. Published by Cosmos, the article explores the significant advancements in artificial intelligence (AI), digital twins, and

How Is Bain Shaping Biotech with Its New $3 Billion Fund?
Management & Regulatory How Is Bain Shaping Biotech with Its New $3 Billion Fund?

Bain Capital Life Sciences has made headlines with the closure of its new $3 billion biotech fund, the largest in its seven-year history. This monumental step aligns with the firm's continuous efforts since its inception in 2016 to bolster the biotech sector by funding ventures that address

Agilent Launches Biopharma CDx Services Lab to Boost Precision Medicine
Tech & Innovation Agilent Launches Biopharma CDx Services Lab to Boost Precision Medicine

Agilent Technologies Inc. has unveiled its new Biopharma CDx Services Lab (BCSL) in Carpinteria, California, marking a significant stride in the field of precision medicine. This state-of-the-art facility is poised to revolutionize the drug development process by streamlining the journey from early

Allspring Significantly Increases Stake in Xeris Biopharma Holdings
Management & Regulatory Allspring Significantly Increases Stake in Xeris Biopharma Holdings

In a notable turn of events, Allspring Global Investments Holdings LLC has dramatically boosted its stake in Xeris Biopharma Holdings, a leading biopharmaceutical company known for its innovative therapies for patients with unmet medical needs. Documented in the latest Form 13F filing with the

Sarepta Predicts Surging Elevidys Demand Despite Q2 Sales Dip
Research & Development Sarepta Predicts Surging Elevidys Demand Despite Q2 Sales Dip

Sarepta Therapeutics recently revealed financial results that indicate lower-than-expected sales for its flagship gene therapy product, Elevidys, designed to treat Duchenne muscular dystrophy (DMD). The sales figures for the second quarter fell short of Wall Street's projections, raising

Can Ivonescimab Become the New Standard in NSCLC Treatment?
Research & Development Can Ivonescimab Become the New Standard in NSCLC Treatment?

In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning i

Rentschler Biopharma Expands Gene Therapy Services with LVV Toolbox
Research & Development Rentschler Biopharma Expands Gene Therapy Services with LVV Toolbox

Rentschler Biopharma has recently unveiled an innovative lentiviral vector (LVV) manufacturing toolbox at its advanced therapies site in Stevenage, United Kingdom, significantly enhancing its service offerings in the gene therapy sector. This strategic expansion complements their established

BioMarin Unveils Strategic Plan for Growth Amid Organizational Rehaul
Management & Regulatory BioMarin Unveils Strategic Plan for Growth Amid Organizational Rehaul

BioMarin Pharmaceutical, a renowned biotech firm known for its pioneering treatments for rare diseases, has recently embarked on a strategic overhaul aimed at revitalizing its growth trajectory. Faced with a period of stagnation marked by significant layoffs and halted projects, the company’s new r

How Is DHL Boosting Boehringer’s Supply Chain Sustainability Goals?
Management & Regulatory How Is DHL Boosting Boehringer’s Supply Chain Sustainability Goals?

In a move that promises to set new standards in supply chain sustainability, DHL Supply Chain has joined forces with biopharmaceutical company Boehringer Ingelheim to transform its warehousing and logistics operations in Australia and New Zealand. The partnership aims to enhance efficiency,

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later